In the rapidly evolving field of cancer research, three-dimensional (3D) in vitro models are emerging as revolutionary platforms that transform our understanding of tumor biology and metastasis. Unlike traditional two-dimensional cultures, these 3D biomaterial-based systems recapitulate the complex interplay of cellular and extracellular cues inherent to human tissues, shedding light on metabolic activity, cellular morphology, and differentiation in unprecedented detail. They offer an intricate environment where cells experience multidimensional interactions and receive mechanical and biochemical support from the surrounding scaffold—fundamental elements that regulate cancer progression.
Self-assembling peptide hydrogels (SAPHs) represent a prime example of such advanced biomaterials, ingeniously designed to mimic the natural extracellular matrix (ECM). By incorporating peptide sequences derived from fibronectin, like the arginine-lysine-aspartate (RKD) motif, researchers have crafted scaffolds that not only support but actively enhance tumor cell behavior. In models using Murine Lewis Lung Carcinoma (LLC) cells alongside murine skeletal muscle fibroblasts (NOR-10 cells), SAPHs have been shown to boost metabolic activity within cultured spheroids, driving invasive phenotypes through upregulated expression of vinculin—an essential cytoskeletal protein involved in cell adhesion and migration.
This engineered microenvironment also prompts an epithelial to mesenchymal transition (EMT), a critical process in cancer metastasis whereby epithelial cancer cells lose their stationary, adherent properties and acquire mesenchymal traits characterized by increased motility and invasiveness. This transition underscores the vital role of the extracellular scaffold in directing cell fate and behavior, though future investigations must validate if similar dynamics are observable with primary human cells and clinical tumor lines to ensure translational relevance.
Beyond promoting cellular signaling, 3D cultures encourage cancer cells to actively reshape their microenvironment through ECM deposition—mimicking a hallmark of in vivo tumor progression. Human breast cancer cell lines, such as MCF-7 and MDA-MB-231, cultured within commercial SAPHs, have been documented producing key ECM proteins, including Collagen I. This activity not only alters the physical matrix but also influences cellular responses, providing a more physiologically relevant model of tumor growth compared to flat culture plates.
One of the most striking features of 3D tumor models lies in their ability to recreate critical microenvironmental stressors, such as hypoxia. Solid tumors rapidly exceed the oxygen diffusion limit, instigating chronic low-oxygen conditions that activate angiogenesis—a process crucial for tumor survival and expansion. The SAPH platform combined with breast cancer cell lines has demonstrated measurable accumulation of HIF-1α, a master transcription factor that orchestrates cellular adaptation to hypoxia. Remarkably, HIF-1α presence was detected as early as one day in culture and significantly intensified by day 14, illustrating how these models authentically simulate tumor hypoxic niches.
This hypoxia-driven angiogenic switch is central to cancer malignancy and is intricately linked with cancer hallmarks such as sustained proliferative signaling and evasion of growth suppressors. The use of SAPH-based 3D systems enables detailed exploration of this biology by providing a tunable scaffold that can mimic the biochemical gradients and mechanical properties of the tumor microenvironment (TME).
Moreover, the combination of precise control over biochemical cues and the physical 3D context in these in vitro systems accelerates the discovery of molecular targets that govern tumor progression. Because these models closely emulate the in vivo tumor architecture and behavior, they provide a strategic platform for high-throughput drug screening. Compared to animal models, SAPH-based 3D cultures offer cost-effective, reproducible, and ethically sound alternatives for evaluating therapeutic efficacy and resistance mechanisms.
Another advantage of SAPHs is their capacity to integrate multiple cell types, allowing the simulation of tumor-stromal interactions that drive disease progression. By co-culturing cancer cells with fibroblasts, immune cells, or endothelial cells within these scaffolds, researchers can dissect the complex cellular crosstalk within the TME. This multi-parametric approach opens new avenues for understanding how stromal components influence cancer cell invasiveness and therapeutic response.
Furthermore, the customizable nature of these peptide hydrogels permits the systematic modification of mechanical stiffness, porosity, and ligand presentation. Such tunability is particularly valuable in studying how mechanical forces and matrix composition affect tumor cell behavior, fostering insights into mechanobiology—a burgeoning area revealing that physical cues are as influential as biochemical signals in cancer development.
By recapitulating the dynamic and heterogeneous landscapes of human tumors within these 3D cultures, scientists can better capture the spatial and temporal variations in cell phenotypes, gene expression, and metabolic states that characterize heterogeneous tumors. This complexity is crucial for understanding tumor evolution, clonal selection, and treatment resistance dynamics.
Notably, the presence of hypoxic zones within SAPH models also permits evaluation of cancer cell adaptation under metabolic stress, encompassing glycolytic shifts, reactive oxygen species regulation, and autophagy processes. Such metabolic reprogramming details are vital for identifying vulnerabilities exploitable by novel targeted therapies.
As investigative tools, SAPH-based 3D cancer models promote the study of invasion and metastasis mechanisms by providing a matrix that reflects the stiffness, topology, and biochemical milieu encountered by cancer cells during dissemination. This congruency enhances the physiological relevance of findings derived from these systems, paving the way for more predictive preclinical evaluations.
Progress in this arena aligns with the broader movement towards personalized medicine. Patient-derived cells or biopsied tumor material integrated into these 3D scaffolds allow for the modeling of individual tumor microarchitectures and drug responses, facilitating the tailoring of therapies to patient-specific tumor characteristics.
In conclusion, biomaterial-based 3D in vitro cancer models, particularly those using sophisticated SAPHs, represent a paradigm shift in cancer research. They not only bridge the gap between oversimplified 2D cultures and complex in vivo conditions but also accelerate discovery by enabling high-throughput, physiologically relevant experimentation. With their ability to emulate key hallmarks of tumor progression—including ECM remodeling, EMT, and hypoxia-induced angiogenesis—these models hold the promise to transform our understanding of cancer and spearhead the development of more effective therapeutics.
Subject of Research: Biomaterial-based 3D in vitro cancer models and their application to studying tumor progression and metastasis.
Article Title: Using biomaterial-based 3D in vitro cancer models to solve current clinical problems.
Article References:
Tipple, E., Slay, E., Tsigkou, O. et al. Using biomaterial-based 3D in vitro cancer models to solve current clinical problems. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03392-3
Image Credits: AI Generated
DOI: 09 April 2026
